News

Bristol Myers Squibb today announced that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, representing a new way of treating this chronic immune-mediated disease.

On March 8^th, we celebrated International Women’s Day. The focus this year is on gender equity and celebrating women telling their stories. The B-NOW Belgian Chapter was thrilled to invite BMS Braine-l’Alleud-based employees to its first Lunch & Learn session of the year.

Cancer treatments are getting better, more diverse and more numerous. Although we still die from cancer, we are also increasingly recovering from it. Research, pharmaceutical companies, governments and private individuals are joining forces to fight cancer together.